The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://jaysonvwcx823722.wikimeglio.com/10300168/retatrutide_vs_tirzepatide_a_comparative_analysis